Devoted to our commitment
Our journey continues to evolve, thanks to constant feedback from our diverse team of experts, who are dedicated to addressing the unmet clinical needs associated with mitochondrial dysfunction
Our vision
We strive to be a global leader in the development of novel mitochondrial cell therapies to treat people stricken with diseases of mitochondrial dysfunction. Every day, together with the world's leading scientists, clinicians, and patient advocacy groups, we are translating our mitochondrial science into meaningful therapies for multiple disorders associated with mitochondrial dysfunction.
Minovia’s logo contains Starlings in Flight.
Flying together, constantly pivoting without colliding, symbolizing close collaboration with constant communication in a dynamic atmosphere.
Key Accomplishments to Date
Our ability to execute is driven by our highly experienced executive team, comprehensive regulatory strategy and clinical development plan in partnerships with key physicians and advisors.
Leadership
Natalie Yivgi-Ohana, PhD
Co-founder & CEO
X
Natalie Yivgi-Ohana, PhDCo-founder & CEO
Natalie is a life science entrepreneur; led the company since incorporation in 2012. Natalie has twenty years’ experience in mitochondrial research and received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010. Natalie founded Minovia with a passion to help children and adults with mitochondrial diseases worldwide.
Noa Sher, PhD
Chief Scientific Officer
X
Noa Sher, PhDChief Scientific Officer
Noa is highly experienced research leader in the cell therapy space and a molecular and cellular biologist by training. Noa received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral studies at the Whitehead Institute, MIT, Cambridge, MA and at the Technion Institute of Technology in Israel. She joined Minovia after several years as head of a research team heading preclinical development and characterization of all clinical-stage products at Pluristem, an Israeli-based cell therapy company.
Nadav Eshkol
VP Operations
X
Nadav EshkolVP Operations
Nadav has more than 10 years of experience in the world of cell therapy, focusing on process development and manufacturing.
He is an expert in developing complex cell therapy processes, optimization, scale-up, tech transfer from development to manufacturing, and process implementation in the manufacturing line, both in start-ups, and in large manufacturing companies.
Before joining Minovia, Nadav led the departments of development and manufacturing at Pluristem, an Israeli-based cell therapy company.
Limor Lior
VP People and Culture
X
Limor LiorVP People and Culture
Limor is an experienced senior HR leader with over 18 years of experience in health-tech companies. She has deep professional knowledge of the biotech field, and personal experience as a manager. Before joining Minovia, Ms. Lior worked at Pluristem Therapeutics in various multi-disciplinary roles, including Manufacturing Manager and Organizational Development Senior Manager, and HRBP. She holds an MSc. in Biotechnology Engineer from the Technion, and she’s a certified coach, mediator and group facilitator. Limor is dedicated to the organization’s people, culture, and their continued development, and has a passion for innovative technologies that impact human life.
Aner Lev
Counsel, Business & Legal Affairs
X
Aner LevCounsel, Business & Legal Affairs
Aner is an experienced Legal Counsel with over seven years in the Hi-tech and biotechnology industries. He adeptly manages legal aspects across various domains, including commercial transactions, clinical trials, security, privacy and corporate governance. Prior to joining Minovia, Aner provided legal advice primarily to technology and life-science companies at Tulchinsky Stern Marciano Cohen Levitski & Co. He holds a Bachelor of Laws from Reichman University and is a licensed lawyer with the Israel Bar Association.
Board of Directors
John Cox, MBA
Chairman of the Board
X
John Cox, MBAChairman of the Board
John joined Minovia Therapeutics in February 2019 and brings over 25 years of experience in biopharmaceuticals. Mr. Cox is currently the Chief Executive Officer of Repertoire Immune Medicines, and was formerly the CEO of Bioverativ, which he built and grew from a new venture with two drugs, Eloctate® and Alprolix® for the treatment of hemophilia A and B. In February 2018 Mr. Cox led Bioverativ to a successful acquisition by Sanofi for $11.6B.
Ilan Ganot, MBA
Board Member
X
Ilan Ganot, MBABoard Member
Ilan is an experienced biotech executive.
He is the former President and CEO of Solid Biosciences, a company he co-founded to develop treatments for Duchenne muscular dystrophy. Prior to starting Solid, Ilan spent a decade as an investment banker at JPMorgan, Nomura and Lehman Brothers in London, Hong Kong and New York. Earlier in his career Ilan practiced law at the Israeli law-firm, Haim Zadok & Co.
Shmuel Cabilly, PhD
Board Member
X
Shmuel Cabilly, PhDBoard Member
Dr. Cabilly graduated from the Hebrew University (Ph.D., Immunology), and was a Post-Doctoral fellow at the City of Hope Research Institute heading a joint City of Hope/Genentech project where he developed a new technology for recombinant antibody production. This invention was patented in world patents, issued in the US 1989 and 2001. Today there are >20 drugs in the market based on this technology, including Herceptin, Rituxan, Traceba, Raptiva and Xolair. Dr. Cabilly was a Co-Founder and a Chief Scientist of Ethrog Biotechnology, where he invented two dry-buffer technologies. The company was later sold to Invitrogen.
Natalie Yivgi-Ohana, PhD
Co-founder, CEO & Board Member
X
Natalie Yivgi-Ohana, PhDCo-founder, CEO & Board Member
Natalie is a life science entrepreneur; led the company since incorporation in 2012. Natalie has twenty years’ experience in mitochondrial research and received her PhD in Biochemistry at The Hebrew University in 2007, after which she performed her postdoctoral fellowship at the Weizmann Institute of Science until 2010. Natalie founded Minovia with passion to help children ans adults with mitochondrial diseases worldwide.
Ephraim Aharonson, PhD
Co-founder & Board Member
X
Ephraim Aharonson, PhDCo-founder & Board Member
Ephraim is an Ex-Deputy Head, Israel Institute for Biological Research. He is a former executive at Siemens Israel and a serial angel investor in Israeli start-up companies.
?
Scientific Advisory Board
Tim Harris, Ph.D.
Chairman of the SAB
X
Tim Harris, Ph.D.Chairman of the SAB
Science and business leader; molecular biologist, biochemist and geneticist.
Tim was SVP Translational Medicine in Biogen and head of R&D in the haematology spinout Bioverativ, which was acquired by Sanofi.
Jose-Carlos Gutierrez-Ramos
SVP, CSO, Danaher
X
Jose-Carlos Gutierrez-RamosSVP, CSO, Danaher
JC has a Ph.D. in immunology from the Universidad Autonoma de Madrid and trained as an immunologist in Spain, Germany and Switzerland. He started his academic career as Assistant Professor of Genetics at Harvard Medical School. He has authored more than 150 peer-reviewed publications.
Catherine Bollard, MD
X
Catherine Bollard, MD
Distinguished Professor and director of Cancer and Transplantation Biology Research, Center for Cancer and Immunology Research, Professor of Pediatrics and of Microbiology, Immunology and Tropical Medicine, Children’s National Hospital
Martin Picard, Ph.D.
X
Martin Picard, Ph.D.
Expert in mitochondrial biology of aging. Associate Professor of Behavioral Medicine in Columbia University Aging Center.
?